In its efforts to discredit the 340B drug pricing program, the pharmaceutical industry has released misleading reports, stating that 340B contributes to high drug prices. As advocates for this program, we know that 340B has lived up to congressional expectations, making a negligible impact on drug prices in the United States. Big pharmaceutical companies continue to push this platform and have the money and … Read More